Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients
Abstract Background Although the efficacy of iron sucrose (IS) and ferric carboxymaltose (FCM) in treating anemia in hemodialysis (HD) patients has been studied individually, a comparison of these two intravenous iron formulations has not yet been performed in HD patients. Methods We performed a ret...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-09-01
|
Series: | BMC Nephrology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12882-018-1045-8 |
id |
doaj-fff6c37198b74854a2722e7fbb25c7e2 |
---|---|
record_format |
Article |
spelling |
doaj-fff6c37198b74854a2722e7fbb25c7e22020-11-24T21:27:41ZengBMCBMC Nephrology1471-23692018-09-011911810.1186/s12882-018-1045-8Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patientsJesse M. G. Hofman0Michele F. Eisenga1Adry Diepenbroek2Ilja M. Nolte3Bastiaan van Dam4Ralf Westerhuis5Stephan J. L. Bakker6Casper F. M. Franssen7Carlo A. J. M. Gaillard8Department of Nephrology, University Medical Center Groningen, University of GroningenDepartment of Nephrology, University Medical Center Groningen, University of GroningenDepartment of Nephrology, University Medical Center Groningen, University of GroningenDepartment of Epidemiology, University Medical Center Groningen, University of GroningenDepartment of Internal Medicine, Medical Center AlkmaarDialysis Center GroningenDepartment of Nephrology, University Medical Center Groningen, University of GroningenDepartment of Nephrology, University Medical Center Groningen, University of GroningenDepartment of Internal Medicine and Dermatology, University Medical Center Utrecht, University of UtrechtAbstract Background Although the efficacy of iron sucrose (IS) and ferric carboxymaltose (FCM) in treating anemia in hemodialysis (HD) patients has been studied individually, a comparison of these two intravenous iron formulations has not yet been performed in HD patients. Methods We performed a retrospective audit on records of 221 stable HD patients from different HD centers in the Netherlands, who were switched from IS to FCM on a 1:1 ratio. To assess the effect of the switch on iron status parameters, data from 3 time points before and 3 time points after the switch were analyzed using linear mixed effects models. Subanalyses were done in 2 subgroups of patients anemic or iron deficient at baseline. Results Hemoglobin increased in all groups (anemic [1.4 g/dL, P < 0.001] iron deficient [0.6 g/dL, P < 0.001]), while the weekly iron dose was significantly lower when patients received FCM compared to IS (48 vs 55 mg/week, P = 0.04). Furthermore, serum ferritin and transferrin saturation increased in all groups (anemic [64 μg/L, 5.0%, P < 0.001] iron deficient [76 μg/L, 3.6%, P < 0.001]). Finally, the darbepoetin α dose decreased significantly in all groups (anemic [− 16 μg/wk., P = 0.01] iron deficient [− 11 μg/wk., P < 0.001]). Conclusions In this real-life study in HD patients, a switch from IS to FCM resulted in an improvement of iron status parameters despite a lower weekly dose of FCM. Furthermore, the ESA dose was reduced during FCM, while hemoglobin levels increased.http://link.springer.com/article/10.1186/s12882-018-1045-8Ferric carboxymaltoseIron sucroseHemodialysisIron statusESA |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jesse M. G. Hofman Michele F. Eisenga Adry Diepenbroek Ilja M. Nolte Bastiaan van Dam Ralf Westerhuis Stephan J. L. Bakker Casper F. M. Franssen Carlo A. J. M. Gaillard |
spellingShingle |
Jesse M. G. Hofman Michele F. Eisenga Adry Diepenbroek Ilja M. Nolte Bastiaan van Dam Ralf Westerhuis Stephan J. L. Bakker Casper F. M. Franssen Carlo A. J. M. Gaillard Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients BMC Nephrology Ferric carboxymaltose Iron sucrose Hemodialysis Iron status ESA |
author_facet |
Jesse M. G. Hofman Michele F. Eisenga Adry Diepenbroek Ilja M. Nolte Bastiaan van Dam Ralf Westerhuis Stephan J. L. Bakker Casper F. M. Franssen Carlo A. J. M. Gaillard |
author_sort |
Jesse M. G. Hofman |
title |
Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients |
title_short |
Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients |
title_full |
Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients |
title_fullStr |
Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients |
title_full_unstemmed |
Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients |
title_sort |
switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients |
publisher |
BMC |
series |
BMC Nephrology |
issn |
1471-2369 |
publishDate |
2018-09-01 |
description |
Abstract Background Although the efficacy of iron sucrose (IS) and ferric carboxymaltose (FCM) in treating anemia in hemodialysis (HD) patients has been studied individually, a comparison of these two intravenous iron formulations has not yet been performed in HD patients. Methods We performed a retrospective audit on records of 221 stable HD patients from different HD centers in the Netherlands, who were switched from IS to FCM on a 1:1 ratio. To assess the effect of the switch on iron status parameters, data from 3 time points before and 3 time points after the switch were analyzed using linear mixed effects models. Subanalyses were done in 2 subgroups of patients anemic or iron deficient at baseline. Results Hemoglobin increased in all groups (anemic [1.4 g/dL, P < 0.001] iron deficient [0.6 g/dL, P < 0.001]), while the weekly iron dose was significantly lower when patients received FCM compared to IS (48 vs 55 mg/week, P = 0.04). Furthermore, serum ferritin and transferrin saturation increased in all groups (anemic [64 μg/L, 5.0%, P < 0.001] iron deficient [76 μg/L, 3.6%, P < 0.001]). Finally, the darbepoetin α dose decreased significantly in all groups (anemic [− 16 μg/wk., P = 0.01] iron deficient [− 11 μg/wk., P < 0.001]). Conclusions In this real-life study in HD patients, a switch from IS to FCM resulted in an improvement of iron status parameters despite a lower weekly dose of FCM. Furthermore, the ESA dose was reduced during FCM, while hemoglobin levels increased. |
topic |
Ferric carboxymaltose Iron sucrose Hemodialysis Iron status ESA |
url |
http://link.springer.com/article/10.1186/s12882-018-1045-8 |
work_keys_str_mv |
AT jessemghofman switchingironsucrosetoferriccarboxymaltoseassociatestobettercontrolofironstatusinhemodialysispatients AT michelefeisenga switchingironsucrosetoferriccarboxymaltoseassociatestobettercontrolofironstatusinhemodialysispatients AT adrydiepenbroek switchingironsucrosetoferriccarboxymaltoseassociatestobettercontrolofironstatusinhemodialysispatients AT iljamnolte switchingironsucrosetoferriccarboxymaltoseassociatestobettercontrolofironstatusinhemodialysispatients AT bastiaanvandam switchingironsucrosetoferriccarboxymaltoseassociatestobettercontrolofironstatusinhemodialysispatients AT ralfwesterhuis switchingironsucrosetoferriccarboxymaltoseassociatestobettercontrolofironstatusinhemodialysispatients AT stephanjlbakker switchingironsucrosetoferriccarboxymaltoseassociatestobettercontrolofironstatusinhemodialysispatients AT casperfmfranssen switchingironsucrosetoferriccarboxymaltoseassociatestobettercontrolofironstatusinhemodialysispatients AT carloajmgaillard switchingironsucrosetoferriccarboxymaltoseassociatestobettercontrolofironstatusinhemodialysispatients |
_version_ |
1725973944870109184 |